We propose to establish a Molecular Resources Core Laboratory (MRCL), with the specific purpose of providing essential reagents, services and assistance with methodologies in support of the six subcomponents of the SCOR. This MRCL is designed as a centralized facility for the instrumentation, specialized molecular biology expertise, and the reagents in order to make it extremely cost effective and highly efficient. MRCL will help in the design and synthesis of oligonucleotides to be used as primers, probes and antisense reagents. We will also provide synthetic oligopeptides and site-specific variants of these peptides to be used as immunogens and as probes in the molecular dissection of the immunological interactions involved in the initiation of immune response or tolerance. A number of specialized vectors for cloning and expression of selected cDNAs, restriction enzymes, and radiolabeled reagents will be prepared and stored in the Core facility and made available to the SCOR investigators. In addition, we will help the principal investigators of the individual projects in carrying out some of the more specialized experiments involving cloning, expression, site-specific mutagenesis of various cDNAs, and other nucleic acid manipulations. Finally, MRCL personnel will be involved in purification, molecular characterization and microsequencing of the rare polypeptide products (e.g. transacting proteins involved in transcriptional control of collagen gene expression). The MRCL, which replaces the Protein Chemistry Core established as part of the earlier funded SCOR, is envisioned to be a microchemical facility with much greater scope to fully satisfy the needs of the current SCOR.

Project Start
1996-09-01
Project End
1999-08-31
Budget Start
1995-10-01
Budget End
1996-09-30
Support Year
10
Fiscal Year
1996
Total Cost
Indirect Cost
Name
University of Tennessee Health Science Center
Department
Type
DUNS #
941884009
City
Memphis
State
TN
Country
United States
Zip Code
38163
Qian, Zhaohui; Latham, Kary A; Whittington, Karen B et al. (2013) Engineered regulatory T cells coexpressing MHC class II:peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis. J Immunol 190:5382-91
Qian, Zhaohui; Latham, Kary A; Whittington, Karen B et al. (2010) An autoantigen-specific, highly restricted T cell repertoire infiltrates the arthritic joints of mice in an HLA-DR1 humanized mouse model of autoimmune arthritis. J Immunol 185:110-8
Tang, Bo; Zhou, Jing; Park, Jeoung-Eun et al. (2009) T cell receptor signaling induced by an analog peptide of type II collagen requires activation of Syk. Clin Immunol 133:145-53
Myers, Linda K; Tang, Bo; Rosioniec, Edward F et al. (2007) An altered peptide ligand of type II collagen suppresses autoimmune arthritis. Crit Rev Immunol 27:345-56
Ye, X J; Tang, B; Ma, Z et al. (2007) The effects of interleukin-18 on rat articular chondrocytes: a study of mRNA expression and protein synthesis of proinflammatory substances. Clin Exp Immunol 149:553-60
Rosloniec, Edward F; Brandstetter, Tilmann; Leyer, Sigmar et al. (2006) Second-generation peptidomimetic inhibitors of antigen presentation effectively treat autoimmune diseases in HLA-DR-transgenic mouse models. J Autoimmun 27:182-95
Ahn, Jae I; Erdin, Robert A; Smith, Richard et al. (2006) Chondrocyte injection in distraction epiphysiolysis (rabbit model). J Orthop Res 24:355-65
Rosloniec, Edward F; Ivey 3rd, Robert A; Whittington, Karen B et al. (2006) Crystallographic structure of a rheumatoid arthritis MHC susceptibility allele, HLA-DR1 (DRB1*0101), complexed with the immunodominant determinant of human type II collagen. J Immunol 177:3884-92
Sakurai, Yoshihiko; Tang, Bo; Rosloniec, Edward F et al. (2006) Molecular characterization of an arthritogenic collagen peptide interacting with I-Ar. Immunology 117:136-42
Sakurai, Yoshihiko; Brand, David D; Tang, Bo et al. (2006) Analog peptides of type II collagen can suppress arthritis in HLA-DR4 (DRB1*0401) transgenic mice. Arthritis Res Ther 8:R150

Showing the most recent 10 out of 122 publications